Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 17

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 17
---
 respect to the May 2024 Series A Warrants not amended by the Warrant Amendment.

Company Information

We are a Delaware corporation, which was initially
formed in 1983 under the laws of the State of Florida as Datalink Systems, Inc. In 1998, we reincorporated in the State of Nevada,
and in 2002, we changed our name to our current name, Applied DNA Sciences, Inc. On December 17, 2008, we reincorporated from
the State of Nevada to the State of Delaware.

Our corporate headquarters are located at
the Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York, where we have established laboratories
for the manufacture and detection of nucleic acids (DNA and mRNA) to support our various business units. In addition, this location also
houses our NYSDOH CLEP-permitted, CLIA-certified clinical laboratory where we perform MDx Testing Services. The mailing address of our
corporate headquarters is 50 Health Sciences Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800.

Implications of Being a Smaller Reporting Company

We are a “smaller reporting company”
as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of
the scaled disclosures available to smaller reporting companies. We will continue to be a “smaller reporting company” until
we have $250 million or more in public float (based on our Common Stock) measured as of the last business day of our most recently
completed second fiscal quarter or, in the event we have no public float (based on our Common Stock) or a public float (based on
our Common Stock) that is less than $700 million, annual revenues of $100 million or more during the most recently completed
fiscal year.

We may choose to take advantage of some, but
not all, of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information
contained herein may be different from the information you receive from other public companies in which you hold stock.

<div align='center'>THE OFFERING</div>

| Common              
 Stock offered by us | 41,640,625                                                                                                                 
 shares of Common Stock issuable upon exercise of the Private Placement Warrants (subject to Warrant Stockholder Approval). |

| Use